Syndax Pharmaceuticals Inc (SNDX)
Data as of , from SEC Form 4 filings.
No open-market insider trades (90d)Watch SNDX
See up to 3 months of SNDX. The 7-day demo opens the 1M and 3M ranges and puts SNDX on your watchlist.
Start 7-day demoLatest SNDX insider trades
About Syndax Pharmaceuticals Inc (SNDX)
Syndax Pharmaceuticals Inc files with the SEC under CIK 0001395937 and is classified as pharmaceutical preparations. We track it alongside the rest of the Health Care sector.
SNDX Form 4 activity by transaction type, last 90 days
No Form 4 activity for SNDX in the last 90 days.
SNDX insider transactions (Form 4)
4821 Form 4 filings on record, the earliest from Jul 16, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Michael A. Metzger - Officer | Option exercise | Common Stock | 32,375 | $6.38 | $207K | |
| Michael A. Metzger - Officer | Open-market sale | Common Stock | 32,375 | $24.24 footnote F2 | $785K | |
| Michael A. Metzger - Officer | Option exercise | Stock Option (Right to buy) | 32,375 | $0.00 | - | |
| ||||||
| Nicholas A.J. Botwood - Officer | Option exercise | Common Stock | 22,515 | $13.82 | $311K | |
| Nicholas A.J. Botwood - Officer | Option exercise | Common Stock | 31,235 | $13.82 | $432K | |
| Nicholas A.J. Botwood - Officer | Open-market sale | Common Stock | 34,280 | $18.00 footnote F2 | $617K | |
| Nicholas A.J. Botwood - Officer | Open-market sale | Common Stock | 31,235 | $18.14 footnote F3 | $567K | |
| Nicholas A.J. Botwood - Officer | Option exercise | Stock options (Right to buy) | 22,515 | $0.00 | - | |
| Nicholas A.J. Botwood - Officer | Option exercise | Stock options (Right to buy) | 31,235 | $0.00 | - | |
| ||||||
 Keith A. Goldan - Officer | Open-market sale | Common Stock | 1,177 | $18.99 | $22K | |
| Michael A. Metzger - Officer | Open-market sale | Common Stock | 6,847 | $18.99 | $130K | |
| Michael A. Metzger - Officer | Open-market sale | Common Stock | 17,159 | $21.03 | $361K | |
| Keith A. Goldan - Officer | Open-market sale | Common Stock | 3,410 | $21.03 | $72K | |
| Michael A. Metzger - Officer | Grant or award | Common Stock | 73,000 footnote F1 | $0.00 | - | |
| Michael A. Metzger - Officer | Grant or award | Common Stock | 144,600 footnote F2 | $0.00 | - | |
| Michael A. Metzger - Officer | Open-market sale | Common Stock | 7,412 | $20.62 | $153K | |
| Michael A. Metzger - Officer | Grant or award | Stock Options (Right to buy) | 440,000 | $20.43 | $8.99M | |
| ||||||
| Keith A. Goldan - Officer | Other | Common Stock | 1,219 | $8.48 | $10K | |
| Keith A. Goldan - Officer | Grant or award | Common Stock | 21,500 footnote F2 | $0.00 | - | |
| Keith A. Goldan - Officer | Grant or award | Common Stock | 30,750 footnote F3 | $0.00 | - | |
| Keith A. Goldan - Officer | Open-market sale | Common Stock | 2,082 | $20.62 | $43K | |
| Keith A. Goldan - Officer | Grant or award | Stock Options (Right to buy) | 118,000 | $20.43 | $2.41M | |
| ||||||
 Jennifer Jarrett | Grant or award | Common Stock | 24,000 footnote F1 | $0.00 | - | |
| ||||||
 Martin H. Huber Jr. | Grant or award | Common Stock | 24,000 footnote F1 | $0.00 | - | |
| ||||||
| Nicholas A.J. Botwood - Officer | Grant or award | Common Stock | 24,000 footnote F1 | $0.00 | - | |
| Nicholas A.J. Botwood - Officer | Grant or award | Common Stock | 36,000 footnote F2 | $0.00 | - | |
| Nicholas A.J. Botwood - Officer | Grant or award | Stock Options (Right to buy) | 144,700 | $20.43 | $2.96M | |
| ||||||
| Dennis Podlesak | Grant or award | Common Stock | 48,000 footnote F1 | $0.00 | - | |
| ||||||
| Aleksandra Rizo | Grant or award | Common Stock | 24,000 footnote F1 | $0.00 | - | |
| ||||||
| Keith Katkin | Grant or award | Common Stock | 24,000 footnote F1 | $0.00 | - | |
| ||||||
| Pierre Legault | Grant or award | Common Stock | 24,000 footnote F1 | $0.00 | - | |
| ||||||
| Keith A. Goldan - Officer | Gift | Common Stock | 1,224 | $0.00 | - | |
| Michael A. Metzger - Officer | Option exercise | Common Stock | 157,307 | $10.90 | $1.71M | |
| Michael A. Metzger - Officer | Open-market sale | Common Stock | 157,307 | $16.41 | $2.58M | |
| Michael A. Metzger - Officer | Option exercise | Stock options (Right to buy) | 157,307 | $0.00 | - | |
| Dennis Podlesak | Option exercise | Common Stock | 19,200 | $7.20 | $138K | |
| Dennis Podlesak | Open-market sale | Common Stock | 19,200 | $14.19 | $273K | |
| Dennis Podlesak | Option exercise | Common Stock | 19,200 | $7.20 | $138K | |
| Dennis Podlesak | Open-market sale | Common Stock | 19,200 | $15.54 | $298K | |
| Dennis Podlesak | Option exercise | Common Stock | 19,200 | $7.20 | $138K | |
| Dennis Podlesak | Open-market sale | Common Stock | 19,200 | $15.84 | $304K | |
| Dennis Podlesak | Option exercise | Stock Options (Right to buy) | 19,200 | $0.00 | - | |
| Dennis Podlesak | Option exercise | Stock Options (Right to buy) | 14,400 | $0.00 | - | |
| Dennis Podlesak | Option exercise | Stock Options (Right to buy) | 4,800 | $0.00 | - | |
| Dennis Podlesak | Option exercise | Stock Options (Right to buy) | 19,200 | $0.00 | - | |
| Keith A. Goldan - Officer | Other | Common Stock | 1,226 | $8.43 | $10K | |
| Keith A. Goldan - Officer | Open-market sale | Common Stock | 1,296 | $9.29 | $12K | |
| Michael A. Metzger - Officer | Open-market sale | Common Stock | 7,534 | $9.29 | $70K | |
Item 2.02, 9.01
Item 8.01, 9.01
Item 1.01, 2.03, 3.02, 9.01
Item 5.02, 5.07, 9.01
Recent SNDX Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR | |
| - | - | - | - |
SNDX insider trading FAQ
What is the latest insider trade for SNDX?
Syndax Pharmaceuticals Inc (SNDX) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-07-09. The full record for SNDX runs to 21 Form 4 filings, the earliest from 2025-07-16. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying SNDX stock?
No insider purchases of SNDX were filed in the last 90 days.
How many insiders are selling SNDX stock?
No insider sales of SNDX were filed in the last 90 days. 15 sales are on record for this company.
Where can I see SNDX SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects SNDX Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Michael A. Metzger view on EDGAR
- - Nicholas A.J. Botwood view on EDGAR
- - Keith A. Goldan view on EDGAR
- - Michael A. Metzger view on EDGAR
- - Michael A. Metzger view on EDGAR
- - Keith A. Goldan view on EDGAR
- - Michael A. Metzger view on EDGAR
- - Keith A. Goldan view on EDGAR
- - Jennifer Jarrett view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where SNDX's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow SNDX with a 7-day demo
- SNDX on your watchlist
- Every SNDX Form 4 filing on record
- Up to 3 months of SNDX price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
